Fujifilm Increases Production Capacity and Establishes New Process Development Facilities with JPY14 Billion ($130M USD) Investment to Support Growing Market Demand
FUJIFILM Corporation (President: Kenji Sukeno) will increase production capacity by investing about JPY14 billion ($130m) in the USA and UK in order to expand the business of its BioCDMO Division.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170417005993/en/
FDBT College Station, Texas cGMP Monoclonal Antibody production facility (Photo: Business Wire)
In the USA, at FUJIFILM Diosynth Biotechnologies Texas, LLC (FDBT), a JPY10 billion ($93m) cGMP production facility has been completed. This facility was built in part with funding from BARDA (Biomedical Advanced Research and Development Authority), an office of the U.S. Department of Health and Human Services, and Fujifilm plans to invest an additional JPY3 billion ($28m) to outfit the facility with mammalian cell culture bioreactors. This facility will start operation at the beginning of 2018. FUJIFILM Diosynth Biotechnologies Texas, LLC (FDBT) was acquired by Fujifilm through FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (FDBU) in 2014. In March of this year, FDBT became a wholly owned subsidiary of FDBU exercising the option early included in the initial deal to take 100% ownership. In addition, a JPY1 billion ($9m) investment will be made to expand the Process Development capabilities at FUJIFILM Diosynth Biotechnologies UK Limited near to its Billingham, UK site. This facility is scheduled to be operational in summer of 2017.
The FDBT facility will be the manufacturing center of excellence for the company’s Saturn Monoclonal Antibody Platform with an initial cell culture capacity of 6,000L (3X 2000L bioreactors). The design of the facility allows for future expansion that can accommodate up to 24,000L of upstream capacity to meet much needed customers’ clinical and commercial demands. In the United Kingdom, the investments include the establishment of a dedicated Mammalian Cell Culture Center of Excellence. These laboratories span over 10,000 sq. ft. and are designed to incorporate the latest high-throughput technologies, including fully automated bioreactors and chromatography systems, to enable for rapid and efficient monoclonal antibody manufacturing process readiness. These assets will enable Fujifilm to provide 'best in class' facilities, technology and operational know how to the industry. They are also a key in our continuing commitment to develop future Medical Counter Measures and Pandemic Flu response candidates for our long term Partners the CIADM (Center for Innovation in Advanced Development and Manufacturing), BARDA and other third party customers.
“FUJIFILM Diosynth Biotechnologies is committed to its vision of being Leaders in the Bio CDMO space,” said Steve Bagshaw, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies, “Our commitment is to transform the CDMO business through innovation and with our great people – providing long term support to our partners fulfilling our core purpose as ‘Partners for Life - Advancing tomorrow’s medicines’.”
Biopharmaceutical production requires the use of advanced manufacturing technologies and facilities for culturing, separation and purification. The number of companies outsourcing process development and manufacturing activities of biopharmaceuticals to CDMOs is increasing. The contract development and manufacturing market is projected to achieve growth of 8% per annum* accordingly.
Fujifilm will continue to grow and expand its existing capabilities in addition to engaging in external collaborations to increase capacity, and it will further develop high efficiency and high productivity technology by combining group technologies, to continue to grow further the business. It is targeting sales of JPY100 billion in its BioCDMO business by 2023.
* According to Fujifilm data
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Billingham, UK, RTP, North Carolina and College Station, Texas. FUJIFILM Diosynth has over twenty five years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com.
FUJIFILM Holdings Corporation, Tokyo, Japan (TOKYO: 4901) brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
FUJIFILM Corporation Corporate Communications Division
TEL +81 3-6271-2000
FUJIFILM Corporation Bio CDMO Division
TEL +81 3-6271-2171
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00 | Pressemelding
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08 | Pressemelding
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 11:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47 | Pressemelding
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom